Psoriatic Arthritis Plasma

Psoriatic Arthritis Plasma for Immune-Mediated Inflammatory Disease Research

Psoriatic Arthritis Plasma is collected from IRB-consented donors clinically diagnosed with psoriatic arthritis and processed within one day of collection to preserve labile analytes such as cytokines, proteins and metabolites. Psoriatic arthritis is an immune-mediated inflammatory spondyloarthritis associated with psoriasis. It is characteristically seronegative, and framing it as an autoantibody-driven autoimmune disease misrepresents its biology.

What Psoriatic Arthritis Plasma Reveals

• Psoriatic arthritis is centred on the IL-23 and Th17 axis rather than on autoantibody production. That mechanism is validated by therapy: IL-17A inhibitors, IL-23 p19 inhibitors and IL-12/23 inhibitors are all effective, alongside TNF inhibitors and JAK inhibitors. Plasma is the practical matrix for the circulating mediators of that axis.
• Rheumatoid factor and anti-CCP antibodies are typically absent, which is the key serological distinction from rheumatoid arthritis. Plasma from psoriatic arthritis donors is therefore valuable as a seronegative inflammatory arthritis comparator in assay specificity work.
• Bone remodelling in psoriatic arthritis is bidirectional: erosion coexists with new bone formation, periostitis, enthesophytes and ankylosis, unlike the purely erosive pattern in rheumatoid arthritis. Circulating bone turnover mediators, including the RANKL and osteoprotegerin axis and Wnt pathway regulators such as Dickkopf-1, reflect that dual biology.
• CRP is frequently normal despite clinically active disease, which is a well-recognised limitation. This is exactly why plasma-based multiplex cytokine, chemokine and proteomic approaches are being pursued as more sensitive activity measures.
• Matrix metalloproteinase-3, calprotectin and angiogenic mediators such as VEGF reflect synovial and entheseal tissue processes that are otherwise only accessible by imaging or biopsy.
• The disease is multi-domain, spanning peripheral arthritis, enthesitis, dactylitis, axial involvement, skin psoriasis and nail disease, with an HLA-B27 association in axial presentations. Plasma from domain-annotated donors lets circulating markers be linked to specific disease compartments rather than to a single global label.

Donor Stratification Available

• Clinical domains involved: peripheral arthritis pattern, enthesitis, dactylitis, axial disease, nail disease
• Disease activity where documented, including DAPSA or minimal disease activity status, tender and swollen joint counts, and CRP or ESR
• Skin disease severity where documented, including PASI or body surface area, and psoriasis subtype
• Treatment status: treatment-naive, methotrexate or other conventional DMARD, TNF inhibitor, IL-17 inhibitor, IL-23 or IL-12/23 inhibitor, JAK inhibitor, or PDE4 inhibitor
• Serology and genetics where documented: RF and anti-CCP negativity confirmed, HLA-B27 status, radiographic erosion or new bone formation
• Matched healthy controls available, along with psoriasis-without-arthritis and rheumatoid arthritis donors for comparison

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed psoriatic arthritis donors
• Processed within one day of collection
• Anticoagulant selection (EDTA, citrate, heparin) available on request
• IRB-approved protocols and informed consent
• Custom aliquot volumes available upon request; volumes reported per lot

De-identified Donor Data

• Verified psoriatic arthritis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Additional psoriatic arthritis-specific metadata available on request

Applications

• IL-23/Th17 axis cytokine profiling, including IL-17A, IL-23, TNF and IL-6
• Bone turnover and Wnt pathway marker research, including RANKL, osteoprotegerin and Dickkopf-1
• MMP-3, calprotectin and tissue remodelling marker quantification
• Disease activity biomarker discovery in CRP-normal active disease
• Seronegative versus seropositive inflammatory arthritis differential marker studies
• Plasma proteomics and metabolomics
• Biologic and JAK inhibitor pharmacodynamic and response biomarker research
• Therapeutic target validation and immunoassay qualification in a disease-state matrix

Other Psoriatic Arthritis Specimen Types

• Psoriatic Arthritis Serum
• Psoriatic Arthritis Whole Blood
• Psoriatic Arthritis PBMC
• Psoriatic Arthritis Leukopak
• Psoriatic Arthritis Bulk Plasma
• Psoriatic Arthritis Synovial Fluid
• Psoriatic Arthritis Skin Punch Biopsy

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Psoriatic arthritis plasma is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human plasma page.